文献速递临床试验与 GCP

二甲双胍与胰岛素用于妊娠期血糖控制(MevIP):一项随机临床试验方案

Metformin versus insulin in glycemic control in pregnancy (MevIP): a randomized clinical trial protocol.
PubMed 文献 · Trials · 2025-02-08

本研究为开放标签随机对照试验方案,在巴西比较二甲双胍与胰岛素治疗妊娠期糖尿病及需药物治疗的2型糖尿病孕妇的血糖控制效果,计划纳入92例(每组46例),主要结局为血糖控制,次要结局包括妊娠期体重增加、高血压综合征、巨大儿和新生儿低血糖。

要点

  • 二甲双胍组为干预组,胰岛素组为常规服务组,主要结局为血糖控制。
  • 计划纳入92例孕妇,每组46例,纳入标准为需药物治疗的妊娠期糖尿病或2型糖尿病、单胎、孕周小于34周。
  • 次要结局包括妊娠期体重增加、高血压综合征、巨大儿和新生儿低血糖。

核心结论

  • 作者预期MevIP研究将证明二甲双胍是巴西人群妊娠期糖尿病治疗的适宜药物,可作为胰岛素的替代选择。

研究设计与样本

  • 开放标签随机对照试验方案,比较二甲双胍组(干预)与胰岛素组(常规服务)治疗妊娠期糖尿病及需药物治疗的2型糖尿病孕妇。
  • 计划样本量为92例孕妇,每组46例;纳入标准为需药物治疗的妊娠期糖尿病或2型糖尿病、单胎妊娠、孕周小于34周。
  • 排除标准为当前正使用任何血糖控制药物、1型糖尿病、对研究药物(二甲双胍或胰岛素)不耐受。
  • 统计分析方法包括意向性治疗分析和两组间比较。
  • 方案已于2023年8月11日在ReBEC前瞻性注册,注册号RBR-3j3cktx。

临床怎么用

  • 原文未据此给出推荐。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gestational diabetes is one of the most prevalent diseases in pregnancy, with an incidence of 5 to 18% in Brazil, and is associated with high morbidity rates. The first-line treatment is insulin, although some recent studies have indicated that metformin might also be effective. Metformin is safe in pregnancy and appears to produce better results than insulin, including reduced gestational weight gain (GWG) and smaller gestational-age newborns. Few studies have been conducted on this topic in low- and middle-income countries. METHODS: We designed an open randomized controlled trial comparing two treatments for pregnant women with type II diabetes mellitus (DM) and gestational diabetes (DMG): the metformin group (intervention) and the insulin group (as a routine service). The primary outcome is glycemic control. The secondary outcomes are GWG, the occurrence of hypertensive syndromes, macrosomia, and neonatal hypoglycemia. The sample will comprise 92 pregnant women, 46 per group. The inclusion criteria will be GDM or type II DM requiring medication for glycemic control, singleton pregnancy, and gestational age under 34 weeks. The exclusion criteria will be current treatment with any medication for glycemic control, type I DM, and intolerance to the study medications (metformin or insulin). Women will be routinely followed during antenatal care, childbirth, and the postpartum period. Statistical analyses will include the intention-to-treat approach and a comparison between the two groups. DISCUSSION: Considering the Brazilian socioeconomic reality and the safety of metformin demonstrated in previous trials, we expect that the MevIP study will demonstrate that metformin is an adequate and appropriate medication for GDM treatment in the Brazilian population, representing an alternative to insulin for GDM. TRIAL REGISTRATION: This protocol has been registered prospectively in ReBEC under the ID RBR-3j3cktx in August 11, 2023.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Amaral-Moreira CFA, Paulino DSM, Pereira BG, et al. Metformin versus insulin in glycemic control in pregnancy (MevIP): a randomized clinical trial protocol. Trials. 2025. PMID: 39923109. doi:10.1186/s13063-025-08752-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。